ALXN News and Press, Alexion Pharmaceuticals Inc. From 02/23/20

Buy The Dip On Coronavirus Fears With the S&P 500 and Nasdaq trading at record highs, we are amazed to see nearly 80% of the companies on our Watch List (over 200 stocks) trading over -20% below their highs made in the past five years. We have already demonstrated to what extent t...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the SVB Leerink Global Healthcare Conference in New York, NY on Tuesday, February 25th, 2020 at 9:30 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: ...

Investment Thesis Alexion Pharmaceuticals, Inc. ( ALXN ) is yet to recover from the last year's patent challenges to the leading revenue generator, Soliris. Over the past twelve months, the stock has lost more than a fifth while the Nasdaq Biotechnology Index has gained nearly a tenth. See...

The investable universe is massive. There are thousands of stocks available to trade right now, all with different business models and reporting periods. No single human could ever keep up with it all. Thankfully, we have computers to do the heavy lifting, and that is precisely what I use mi...

I last covered Alexion Pharmaceuticals (ALXN) in October 2018 . Since then, much has changed for the pharmaceutical industry as well as the company. Despite the rise in headwinds, I continue to believe in Alexion Pharmaceuticals' growth story. In fact, I believe that this can be an optimal en...

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company that researches and manufactures treatments of severe and rare health disorders; I consider this an undervalued growth stock, notes Crista Huff , editor of Cabot Undervalued Stocks Advisor . The company ju...

In early January, Apellis Pharmaceuticals (NASDAQ: APLS) announced late-stage clinical results demonstrating that its lead drug candidate bested a market-leading product from Alexion Pharmaceuticals (NASDAQ: ALXN) as a treatment for paroxysmal nocturnal hemoglobinuria (PNH). The results ...

Of all escape mechanisms, death is the most efficient. ” - Henry Louis Mencken The stock of Alexion Therapeutics ( ALXN ) slipped to under the $100 last week despite a significant Q4 earnings beat. Part of this recent decline is due to the huge hit small and midcap biotech stoc...

Alexion Pharmaceuticals Inc (ALXN) Q4 2019 Earnings Conference Call January 30, 2020 07:30 AM ET Company Participants Morgan Sanford - Director of Investor Relations Ludwig Hantson - Chief Executive Officer Aradhana Sarin - Chief Financial Officer John Orloff - Global Head of R...

Image source: The Motley Fool. Alexion Pharmaceuticals Inc   (NASDAQ: ALXN) Q4 2019 Earnings Call Jan 30, 2020 , 7:30 a.m. ET Operator Continue reading